- Latest Stories
- Commentary and Analysis
10:45AM ET 5/11/2022 MT NewswiresAbbVie (ABBV) said Wednesday its upadacitinib oral therapy for adults with moderate to severe Crohn's disease showed "significantly higher" endoscopic...
1:35PM ET 5/02/2022 MT NewswiresCFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as...
8:39AM ET 5/02/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
8:30AM ET 5/02/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
3:58PM ET 4/29/2022 MT NewswiresHealth care stocks were mostly lower this afternoon, with the NYSE Health Care Index sinking 2.0% and the SPDR Health Care Select Sector ETF (XLV) down...
3:06PM ET 4/29/2022 MT NewswiresAbbVie (ABBV) said Friday that the Food and Drug Administration has approved the use of Rinvoq to treat adults with active ankylosing spondylitis, an...
2:23PM ET 4/29/2022 MT NewswiresAbbVie's (ABBV) stock price dropped more than 8% in Friday afternoon trading after the drugmaker lowered its full-year profit outlook while its Q2 guidance...
1:25PM ET 4/29/2022 MT NewswiresHealth care stocks were mostly lower this afternoon, with the NYSE Health Care Index sinking 1.7% and the SPDR Health Care Select Sector ETF (XLV) down...
1:17PM ET 4/29/2022 MT NewswiresHealth care stocks were mostly lower this afternoon, with the NYSE Health Care Index sinking 1.7% while the SPDR Health Care Select Sector ETF (XLV) was...
1:03PM ET 4/29/2022 MT NewswiresAbbVie (ABBV) on Friday cut its full-year profit outlook and outlined second-quarter guidance that missed Wall Street's estimates after the drugmaker's...